Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Terminated NCT04339426

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

Conditions: Covid19

Sex: All

Ages: 18 Years – 95 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 3

Sponsor: HonorHealth Research Institute

Location: HonorHealth Scottsdale Arizona

Summary

This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection. The first combination to be evaluated is atovaquone and azithromycin.

Eligibility Criteria

Inclusion Criteria: * Male and Female patients age 18 years or older * COVID-19 confirmed positive test results * High risk for complications including with Medium (5-6) or High (More than or equal to 7) NEWS score * Hematology criteria: ANC \>500 cells/mcl, HGB \>9 g/dl, Platelet count \>75,000/mcl * Metabolic criteria: Serum creatinine \30 ml/min, AST/ALT \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04339426). StuddyBuddy aggregates publicly available trial information.